Furniture Ros

Furniture Ros company information, Employees & Contact Information

Explore related pages

Related company profiles:

For unique people, unique homes. La vie en ROS. Making your home different.

Company Details

Employees
83
Founded
-
Address
Ctra. Lleida-Puigcerdà, Km. 47, Artesa De Segre,lleida 25730,spain
Industry
Furniture And Home Furnishings Manufacturing
NAICS
Furniture and Related Product Manufacturing
Website
ros1.com
HQ
Artesa de Segre, Lleida
Looking for a particular Furniture Ros employee's phone or email?

Furniture Ros Questions

News

ROS1 and Lung Cancer - American Lung Association

ROS1 and Lung Cancer American Lung Association

Zidesamtinib Elicits Responses in ROS1-Positive NSCLC - Cure Today

Zidesamtinib Elicits Responses in ROS1-Positive NSCLC Cure Today

Zidesamtinib Demonstrates Responses in ROS1-Positive NSCLC After Prior TKI Treatment - The ASCO Post

Zidesamtinib Demonstrates Responses in ROS1-Positive NSCLC After Prior TKI Treatment The ASCO Post

Ibtrozi Approved for Advanced ROS1 -Positive NSCLC - Pulmonology Advisor

Ibtrozi Approved for Advanced ROS1 -Positive NSCLC Pulmonology Advisor

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC - Medical Xpress

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC Medical Xpress

Ibtrozi Emerging as New Standard for ROS1-Mutated Lung Cancer - Cure Today

Ibtrozi Emerging as New Standard for ROS1-Mutated Lung Cancer Cure Today

Zidesamtinib Shows Early Signs of Efficacy, Durability in Pretreated ROS1-Positive NSCLC - Oncology News Central

Zidesamtinib Shows Early Signs of Efficacy, Durability in Pretreated ROS1-Positive NSCLC Oncology News Central

ROS1-Directed Therapies Lead the Way in NSCLC - Targeted Oncology

ROS1-Directed Therapies Lead the Way in NSCLC Targeted Oncology

Ibtrozi May Address Unmet Needs In ROS1-Positive Non-Small Cell Lung Cancer - Cure Today

Ibtrozi May Address Unmet Needs In ROS1-Positive Non-Small Cell Lung Cancer Cure Today

Predicting ROS1 and ALK fusions in NSCLC from H&E slides with a two-step vision transformer approach - Nature

Predicting ROS1 and ALK fusions in NSCLC from H&E slides with a two-step vision transformer approach Nature

Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC - The American Journal of Managed Care® (AJMC®)

Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC The American Journal of Managed Care® (AJMC®)

The 5-methylcytosine DNA glycosylase ROS1 prevents paternal genome hypermethylation in Arabidopsis endosperm - Genome Biology

The 5-methylcytosine DNA glycosylase ROS1 prevents paternal genome hypermethylation in Arabidopsis endosperm Genome Biology

Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer - The New England Journal of Medicine

Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer The New England Journal of Medicine

Repotrectinib Shrinks ROS1-Positive NSCLC Tumors - National Cancer Institute (.gov)

Repotrectinib Shrinks ROS1-Positive NSCLC Tumors National Cancer Institute (.gov)

Positive lung cancer data sets up rolling FDA filing for Nuvalent's ROS1-targeted drug - FirstWord Pharma

Positive lung cancer data sets up rolling FDA filing for Nuvalent's ROS1-targeted drug FirstWord Pharma

Selecting First-Line Therapy for ROS1 Fusion–Positive NSCLCs - ASCO Daily News

Selecting First-Line Therapy for ROS1 Fusion–Positive NSCLCs ASCO Daily News

Current Targeted Therapy Options in ROS1-Positive NSCLC - Pharmacy Times

Current Targeted Therapy Options in ROS1-Positive NSCLC Pharmacy Times

Progress of non-small-cell lung cancer with ROS1 rearrangement - Frontiers

Progress of non-small-cell lung cancer with ROS1 rearrangement Frontiers

Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domain - Nature

Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domain Nature

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers - Nature

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers Nature

FDA Approves Ibtrozi for ROS1-Positive Lung Cancer - Cancer Health

FDA Approves Ibtrozi for ROS1-Positive Lung Cancer Cancer Health

ROS1 immunohistochemistry as a potential predictive biomarker for ROS1-targeted therapy in breast cancer: impact of antibody clone selection - Wiley Online Library

ROS1 immunohistochemistry as a potential predictive biomarker for ROS1-targeted therapy in breast cancer: impact of antibody clone selection Wiley Online Library

Role of the Arabidopsis DNA glycosylase/lyase ROS1 in active DNA demethylation - PNAS

Role of the Arabidopsis DNA glycosylase/lyase ROS1 in active DNA demethylation PNAS

The association of ROS1 mutation with cancer immunity and its impact on the efficacy of pan-cancer immunotherapy - Journal of Translational Medicine

The association of ROS1 mutation with cancer immunity and its impact on the efficacy of pan-cancer immunotherapy Journal of Translational Medicine

Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing - BMC Cancer

Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing BMC Cancer

FDA Approves Repotrectinib for ROS1 -Positive NSCLC - Medscape

FDA Approves Repotrectinib for ROS1 -Positive NSCLC Medscape

FDA Approves New Drug for Non-Small Cell Lung Cancer With ROS1 Fusions - Memorial Sloan Kettering Cancer Center

FDA Approves New Drug for Non-Small Cell Lung Cancer With ROS1 Fusions Memorial Sloan Kettering Cancer Center

Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors - Wiley Online Library

Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors Wiley Online Library

Entrectinib in ROS1 -positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial - Nature

Entrectinib in ROS1 -positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial Nature

Direct identification of ALK and ROS1 fusions in non-small cell lung cancer from hematoxylin and eosin-stained slides using deep learning algorithms | Modern Pathology - Nature

Direct identification of ALK and ROS1 fusions in non-small cell lung cancer from hematoxylin and eosin-stained slides using deep learning algorithms | Modern Pathology Nature

Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance | npj Precision Oncology - Nature

Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance | npj Precision Oncology Nature

Repotrectinib effective in ROS1-fusion-positive NSCLC - Nature

Repotrectinib effective in ROS1-fusion-positive NSCLC Nature

ROS1-dependent cancers — biology, diagnostics and therapeutics - Nature

ROS1-dependent cancers — biology, diagnostics and therapeutics Nature

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition - Nature

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition Nature

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models - Nature

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models Nature

Crizotinib in ROS1 -Rearranged Non–Small-Cell Lung Cancer - The New England Journal of Medicine

Crizotinib in ROS1 -Rearranged Non–Small-Cell Lung Cancer The New England Journal of Medicine

NICE shoots down Pfizer's Xalkori in ROS1-positive patients, inviting a CDF proposal instead - Fierce Pharma

NICE shoots down Pfizer's Xalkori in ROS1-positive patients, inviting a CDF proposal instead Fierce Pharma

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials - The Lancet

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials The Lancet

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1 - The New England Journal of Medicine

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1 The New England Journal of Medicine

RET, ROS1 and ALK fusions in lung cancer - Nature

RET, ROS1 and ALK fusions in lung cancer Nature

Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers - Nature

Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers Nature

Top Furniture Ros Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant